Insider Selling: Axsome Therapeutics (NASDAQ:AXSM) Insider Sells 7,500 Shares of Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM) insider Ari Maizel sold 7,500 shares of the firm’s stock in a transaction on Wednesday, January 21st. The stock was sold at an average price of $184.44, for a total value of $1,383,300.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Axsome Therapeutics Stock Down 0.5%

Shares of AXSM stock traded down $1.02 during mid-day trading on Friday, hitting $185.96. The stock had a trading volume of 426,610 shares, compared to its average volume of 855,001. Axsome Therapeutics, Inc. has a 12-month low of $86.99 and a 12-month high of $191.50. The firm has a market capitalization of $9.37 billion, a P/E ratio of -39.82, a price-to-earnings-growth ratio of 9.86 and a beta of 0.44. The firm’s 50-day moving average is $159.39 and its two-hundred day moving average is $133.10. The company has a debt-to-equity ratio of 1.66, a current ratio of 1.57 and a quick ratio of 1.50.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings results on Monday, November 3rd. The company reported ($0.94) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.12). Axsome Therapeutics had a negative net margin of 40.90% and a negative return on equity of 277.31%. The firm had revenue of $170.99 million for the quarter, compared to analysts’ expectations of $162.96 million. The business’s quarterly revenue was up 63.2% compared to the same quarter last year. On average, analysts predict that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on AXSM shares. UBS Group boosted their price target on Axsome Therapeutics from $163.00 to $248.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. HC Wainwright boosted their target price on shares of Axsome Therapeutics from $200.00 to $260.00 and gave the stock a “buy” rating in a report on Tuesday. B. Riley started coverage on shares of Axsome Therapeutics in a research report on Wednesday, October 1st. They set a “buy” rating and a $179.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Axsome Therapeutics in a research report on Wednesday. Finally, Robert W. Baird set a $209.00 price objective on shares of Axsome Therapeutics in a research note on Tuesday, January 13th. Nineteen research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $203.17.

Institutional Investors Weigh In On Axsome Therapeutics

A number of large investors have recently made changes to their positions in the stock. Stanley Laman Group Ltd. purchased a new stake in Axsome Therapeutics in the third quarter valued at approximately $2,125,000. Swiss National Bank lifted its stake in Axsome Therapeutics by 6.9% during the 2nd quarter. Swiss National Bank now owns 65,200 shares of the company’s stock valued at $6,806,000 after acquiring an additional 4,200 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Axsome Therapeutics by 55.4% in the second quarter. Bank of New York Mellon Corp now owns 203,632 shares of the company’s stock worth $21,257,000 after acquiring an additional 72,609 shares during the period. Assenagon Asset Management S.A. increased its stake in shares of Axsome Therapeutics by 62.9% in the third quarter. Assenagon Asset Management S.A. now owns 294,771 shares of the company’s stock worth $35,800,000 after acquiring an additional 113,811 shares during the period. Finally, Los Angeles Capital Management LLC raised its holdings in shares of Axsome Therapeutics by 154.5% during the second quarter. Los Angeles Capital Management LLC now owns 4,424 shares of the company’s stock worth $462,000 after purchasing an additional 2,686 shares during the last quarter. 81.49% of the stock is owned by hedge funds and other institutional investors.

More Axsome Therapeutics News

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Piper Sandler is bullish ahead of a likely Auvelity label expansion by April 30, which would expand the approved uses for Axsome’s depression drug and could materially increase addressable market and sales expectations. Piper Sandler Bullish on Axsome Therapeutics (AXSM) Ahead of Likely Auvelity Label Expansion by April 30
• Positive Sentiment: HC Wainwright has increased some earnings estimates and reiterated a Buy rating with a $260 target, signaling conviction in Axsome’s medium-term revenue trajectory and valuation upside. This analyst support is likely propping up investor sentiment despite volatility. HC Wainwright Brokers Increase Earnings Estimates for AXSM
• Positive Sentiment: Related coverage from HC Wainwright and other outlets highlights expectations for strong price appreciation and has coincided with recent share strength, providing momentum that could support further gains if clinical and label catalysts materialize. HC Wainwright Forecasts Strong Price Appreciation for Axsome Therapeutics (NASDAQ:AXSM) Stock
• Positive Sentiment: Axsome recently hit a new 12‑month high following analyst upgrades, reflecting elevated optimism from the sell side which can attract momentum and institutional interest. Axsome Therapeutics (NASDAQ:AXSM) Hits New 12-Month High Following Analyst Upgrade
• Neutral Sentiment: Analyst roundup pieces summarize diverse views from ~14 analysts; consensus leans positive but shows dispersion in price targets and timing, indicating investor outcomes depend heavily on upcoming regulatory/label and sales data. 3AXSM : Expert Outlook: Axsome Therapeutics Through The Eyes Of 14 Analysts
• Negative Sentiment: HC Wainwright’s detailed model changes are mixed — while they raised several quarterly and FY2025 estimates and the target, they also trimmed forecasts for certain quarters (notably Q2 and Q3 adjustments). That mix introduces near-term earnings uncertainty that can create volatility until clinical/label outcomes and actual sales datapoints arrive.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.